Non-Communicable Diseases (NCDs)

Sandeep P. Kishore, Ph.D.Young Professionals Chronic Disease Network

Universities Allied for Essential Medicines

The Global Burden of Disease (Mortality)

Disease Deaths (x 10^6) % of total1. Ischemic heart disease 7.2 12.22. Cerebrovascular disease 5.7 9.73. Lower respiratory infections 4.2 7.14. COPD 3.0 5.15. Diarrheal Diseases 2.2 3.76. HIV/AIDS 2.0 3.57. Tuberculosis 1.5 2.58. Trachea, bronchus and lung cancers 1.3 2.39. Road Traffic Accidents 1.3 2.210.Premature birth/low birth weight 1.2 2.0…14. Malaria 0.9 1.515. Birth trauma 0.9 1.516. Self-inflicted injuries 0.8 1.4

$7536

$30

$19

Burden of Disease

1. Tobacco (1 in 10 deaths, women,youth)

2. Poor diets (high-fat, high-salt, sugary)

3. Inadequate physical activity4. Harmful use of alcohol

10/2010 – Modalities Resolution for NCD HLM @ UNGA

4/2011– WHO Global Forum on NCDs (IFPMA chairs A2M session; civil society groups are pharma-funded; affirm IP non-issue…))8/2011 – UN political draft declaration negotiations stall (trade issues)

TRIPS flex/Doha/IPR @ center. Bullying by EU/USA.

9/2011 – HLM @ UNGA. References to Doha excised. HPV/HBV vaccines called for. First youth rally on NCDs @ UN.

1/2012 – WHO EB (Targets/commitments) [Access Indicator]; for global monitoring system finalized by WHA 5/20126/2012 – Rio+20 Sustainable Development (MDGs)/ UNDP12/2012 – Proposals for a global partnership (e.g. Stop NCDs); [COI]9/2014 – Review of UN NCD HLM

Short-term:

1. Focus on influencing the 2012 WHO targets/commitments process. Formulate and lobby for time-bound, numerical A2M indicator.

2. Drug-specific: heart disease (fixed dose combination; polypill); cancer (HPV; HBV vaccines; herceptin, imatinib); diabetes (insulin);

asthma (patented inhaler technology). CANCER AS PRIORITY.

3. Feed outrage at surgical removal of Doha Declaration from NCD political declaration into statement / press release from this meeting

Long-term:

1. Aggressively call out/resist pharmaceutical COI in public sector policy-making / civil society actors and via nodal patient advocacy groups.

2. NCDs framed in human rights context (e.g. youth/students)

3. Global mapping re: price/generic manufacturers/tech transfer

OSI Scoping paper on disease-/ field-specific strategies

4. Beyond IP: Procurement/Stop Stock Out campaigns for off patent meds (e.g.aspirin, beta blockers)